151. SHP-1, a novel peptide isolated from seahorse inhibits collagen release through the suppression of collagenases 1 and 3, nitric oxide products regulated by NF-kappaB/p38 kinase.
- Author
-
Ryu B, Qian ZJ, and Kim SK
- Subjects
- Amino Acid Sequence, Animals, Cartilage chemistry, Cartilage metabolism, Cell Line drug effects, Collagen drug effects, Dose-Response Relationship, Drug, Extracellular Matrix metabolism, Humans, Matrix Metalloproteinase Inhibitors, Matrix Metalloproteinases metabolism, Molecular Sequence Data, NF-kappa B antagonists & inhibitors, Nitric Oxide Synthase Type II metabolism, Peptides genetics, Peptides pharmacology, Signal Transduction drug effects, p38 Mitogen-Activated Protein Kinases antagonists & inhibitors, Collagen metabolism, Collagenases metabolism, Matrix Metalloproteinase 13 metabolism, NF-kappa B metabolism, Nitric Oxide metabolism, Peptides metabolism, Smegmamorpha, p38 Mitogen-Activated Protein Kinases metabolism
- Abstract
Considerable efforts have been taken to identify natural peptides as potential bioactive substances. In this study, novel peptide (SHP-1) derived from seahorse (Hippocampus, Syngnathidae) hydrolysate was explored for its inhibitory effects on collagen release in arthritis with the investigation of its underlying mechanism of action. The efficacy of SHP-1 was determined on cartilage protective effects such as inhibition of collagen and GAG release. SHP-1 was able to suppress not only the expression of collagenases 1 and 3, but also the production of NO via down-regulation of iNOS. However, it presented an irrelevant effect on the level of GAG release in chondrocytic and osteoblastic cells. Inhibition of collagen release by SHP-1 is associated with restraining the phosphorylation of NF-kappaB and p38 kinase cascade. Therefore, it could be suggested that SHP-1 has a potential to be used in arthritis treatment.
- Published
- 2010
- Full Text
- View/download PDF